Unpicking the Complexity of Importer of Record Processes in Globalised Clinical Supply Chains

The number of countries serving as clinical study locations outside of the United States has more than doubled in the space of ten years. There are many factors that contribute to this market trend, which sees the average phase III trial spanning 34 countries with 1,000+ patients. Cost reduction is one, with estimates suggesting that a clinical site in India can be up to ten times cheaper than a US-based facility. The ability to deliver drugs to market faster is another. Greater geographical reach creates an abundance of potential for study participants, leading to faster and more effective patient enrolment. This enables quicker, more cost-effective development and approval of drugs that support the advancement of human health. Download to find out more.